alexa Engineering Enhanced Vaccine Cell Lines For Vaccine Preventable Viral Diseases
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th World Congress on Virology
October 06-08, 2014 Hilton San Antonio Airport, TX, USA

Ralph A Tripp
Keynote: J Antivir Antiretrovir
DOI: 10.4172/1948-5964.S1.019
One of the greatest hurdles to eliminating vaccine-preventable disease is manufacturing cost. RNA interference provides a strategy to create affordable vaccines where high throughput assay platforms can be used to identify gene knockdown events that increase vaccine virus replication. The results generated can then be exploited to create stable knockout vaccine cell lines capable of sustained virus production at increased titers. This presentation will discuss the findings of genome-wide small interfering RNA (siRNA) screens that targeted all individual genes in the vaccine cell line genome to identify gene knockdown events that increase production of viral progeny by >2 logs for poliovirus measles virus, influenza virus and rotavirus. The studies will focus on our proof-of-principle studies with poliovirus which identified over a dozen genes that could be modulated to increase poliovirus production between 5 and 60 fold thereby demonstrating that these goals are achievable. We believe that replacing the older historic vaccine cell lines with a new genetically engineered construct has the potential to fundamentally change vaccine development and supply by dramatically increasing available stocks for vaccine preventable viral diseases. In addition, these studies increase our understanding of the biology of virus replication; innate host defense mechanisms, hostpathogen interactions, and viral pathogenesis thereby further facilitating drug and vaccine discovery and development.
Ralph A Tripp is a Professor and Georgia Research Alliance Eminent Scholar and Chair in Vaccine and Therapeutic Studies in the Department of Infectious Diseases at the University of Georgia (UGA). He is an Associate Director of the Regional Center of Excellence for Influenza Virus Research and Surveillance, of the Center of Molecular Medicine, and of Biomedical Health Sciences Institute. Dr. Tripp is an Adjunct Professor in the Virus Research Group at the University of Canberra, and at the School of Infection & Host Defense at the University of Liverpool, and the Molecular & Medical Research Centre, Deakin University AUS.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version